Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer
Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1986-02, Vol.53 (2), p.197-202 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 202 |
|---|---|
| container_issue | 2 |
| container_start_page | 197 |
| container_title | British journal of cancer |
| container_volume | 53 |
| creator | Haglund, C Roberts, P J Kuusela, P Scheinin, T M Mäkelä, O Jalanko, H |
| description | Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high levels (greater than 500 U ml-1) were seen in 56% of these patients. Elevated levels were also seen in benign diseases (22%), especially in patients with extrahepatic cholestasis (up to 440 U ml-1). Hepatocellular jaundice and pancreatitis were associated with normal values (84% of the patients), or with only slightly elevated CA 19-9 levels (up to 88 U ml-1). The CA 19-9 test can be useful as an additional diagnostic tool for the detection of pancreatic cancer. Preliminary results suggest that the CA 19-9 assay can be used in the monitoring of surgically treated patients. |
| doi_str_mv | 10.1038/bjc.1986.35 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2001324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76748481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-d696e38963e73628d789604bb26baf2145d530d55c7a3aef8b2262b99c5d65933</originalsourceid><addsrcrecordid>eNqFkctL7DAUxoMoOj5WruVmIW60Y96PjSDD-ADBja5DmqbauW06Jq3gf2-GGQbv4uIqJ3y_fOfkfACcYjTFiKrrcuGmWCsxpXwHTDCnpMCKyF0wQQjJAmmCDsBhSot81UjJfbBPGRdSyQmYzT9tO9qh6QPsazi7hVgXGtoELUw-jh0cxq4fI-xs_OsjbAJc2uCiz08cdLn08Rjs1bZN_mRzHoHXu_nL7KF4er5_nN0-FY5pORSV0MJTpQX1kgqiKplrxMqSiNLWBDNecYoqzp201PpalYQIUmrteCW4pvQI3Kx9l2PZ-cr5METbmmVs8nBfpreN-VcJzbt56z8NQQhTwrLBxcYg9h-jT4PpmuR829rg-zEZKSRTTOFfQcwok0StHC_XoIt9StHX22kwMqtwTA7HrMIxlGf67OcHtuwmjayfb3SbnG3rmNfbpC2mBEcUiYxdrbGUlfDmo1nkhEJe_X-6_lnjwQ5j9Fu7zKyQTHwD5LSvAQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14347284</pqid></control><display><type>article</type><title>Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Haglund, C ; Roberts, P J ; Kuusela, P ; Scheinin, T M ; Mäkelä, O ; Jalanko, H</creator><creatorcontrib>Haglund, C ; Roberts, P J ; Kuusela, P ; Scheinin, T M ; Mäkelä, O ; Jalanko, H</creatorcontrib><description>Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high levels (greater than 500 U ml-1) were seen in 56% of these patients. Elevated levels were also seen in benign diseases (22%), especially in patients with extrahepatic cholestasis (up to 440 U ml-1). Hepatocellular jaundice and pancreatitis were associated with normal values (84% of the patients), or with only slightly elevated CA 19-9 levels (up to 88 U ml-1). The CA 19-9 test can be useful as an additional diagnostic tool for the detection of pancreatic cancer. Preliminary results suggest that the CA 19-9 assay can be used in the monitoring of surgically treated patients.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1986.35</identifier><identifier>PMID: 3456787</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Alkaline Phosphatase - blood ; Antigens, Neoplasm - analysis ; Antigens, Tumor-Associated, Carbohydrate ; Biliary Tract Diseases - immunology ; Bilirubin - blood ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoembryonic Antigen - analysis ; Drug Resistance ; Epidemiology ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Jaundice - immunology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Molecular Medicine ; Oncology ; original-article ; Pancreatic Neoplasms - immunology ; Pancreatitis - immunology ; Time Factors ; Tumors</subject><ispartof>British journal of cancer, 1986-02, Vol.53 (2), p.197-202</ispartof><rights>Cancer Research Campaign 1986</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-d696e38963e73628d789604bb26baf2145d530d55c7a3aef8b2262b99c5d65933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001324/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001324/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8650306$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3456787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haglund, C</creatorcontrib><creatorcontrib>Roberts, P J</creatorcontrib><creatorcontrib>Kuusela, P</creatorcontrib><creatorcontrib>Scheinin, T M</creatorcontrib><creatorcontrib>Mäkelä, O</creatorcontrib><creatorcontrib>Jalanko, H</creatorcontrib><title>Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high levels (greater than 500 U ml-1) were seen in 56% of these patients. Elevated levels were also seen in benign diseases (22%), especially in patients with extrahepatic cholestasis (up to 440 U ml-1). Hepatocellular jaundice and pancreatitis were associated with normal values (84% of the patients), or with only slightly elevated CA 19-9 levels (up to 88 U ml-1). The CA 19-9 test can be useful as an additional diagnostic tool for the detection of pancreatic cancer. Preliminary results suggest that the CA 19-9 assay can be used in the monitoring of surgically treated patients.</description><subject>Alkaline Phosphatase - blood</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Antigens, Tumor-Associated, Carbohydrate</subject><subject>Biliary Tract Diseases - immunology</subject><subject>Bilirubin - blood</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoembryonic Antigen - analysis</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Jaundice - immunology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>original-article</subject><subject>Pancreatic Neoplasms - immunology</subject><subject>Pancreatitis - immunology</subject><subject>Time Factors</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctL7DAUxoMoOj5WruVmIW60Y96PjSDD-ADBja5DmqbauW06Jq3gf2-GGQbv4uIqJ3y_fOfkfACcYjTFiKrrcuGmWCsxpXwHTDCnpMCKyF0wQQjJAmmCDsBhSot81UjJfbBPGRdSyQmYzT9tO9qh6QPsazi7hVgXGtoELUw-jh0cxq4fI-xs_OsjbAJc2uCiz08cdLn08Rjs1bZN_mRzHoHXu_nL7KF4er5_nN0-FY5pORSV0MJTpQX1kgqiKplrxMqSiNLWBDNecYoqzp201PpalYQIUmrteCW4pvQI3Kx9l2PZ-cr5METbmmVs8nBfpreN-VcJzbt56z8NQQhTwrLBxcYg9h-jT4PpmuR829rg-zEZKSRTTOFfQcwok0StHC_XoIt9StHX22kwMqtwTA7HrMIxlGf67OcHtuwmjayfb3SbnG3rmNfbpC2mBEcUiYxdrbGUlfDmo1nkhEJe_X-6_lnjwQ5j9Fu7zKyQTHwD5LSvAQ</recordid><startdate>19860201</startdate><enddate>19860201</enddate><creator>Haglund, C</creator><creator>Roberts, P J</creator><creator>Kuusela, P</creator><creator>Scheinin, T M</creator><creator>Mäkelä, O</creator><creator>Jalanko, H</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19860201</creationdate><title>Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer</title><author>Haglund, C ; Roberts, P J ; Kuusela, P ; Scheinin, T M ; Mäkelä, O ; Jalanko, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-d696e38963e73628d789604bb26baf2145d530d55c7a3aef8b2262b99c5d65933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Alkaline Phosphatase - blood</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Antigens, Tumor-Associated, Carbohydrate</topic><topic>Biliary Tract Diseases - immunology</topic><topic>Bilirubin - blood</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoembryonic Antigen - analysis</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Jaundice - immunology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>original-article</topic><topic>Pancreatic Neoplasms - immunology</topic><topic>Pancreatitis - immunology</topic><topic>Time Factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haglund, C</creatorcontrib><creatorcontrib>Roberts, P J</creatorcontrib><creatorcontrib>Kuusela, P</creatorcontrib><creatorcontrib>Scheinin, T M</creatorcontrib><creatorcontrib>Mäkelä, O</creatorcontrib><creatorcontrib>Jalanko, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haglund, C</au><au>Roberts, P J</au><au>Kuusela, P</au><au>Scheinin, T M</au><au>Mäkelä, O</au><au>Jalanko, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1986-02-01</date><risdate>1986</risdate><volume>53</volume><issue>2</issue><spage>197</spage><epage>202</epage><pages>197-202</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high levels (greater than 500 U ml-1) were seen in 56% of these patients. Elevated levels were also seen in benign diseases (22%), especially in patients with extrahepatic cholestasis (up to 440 U ml-1). Hepatocellular jaundice and pancreatitis were associated with normal values (84% of the patients), or with only slightly elevated CA 19-9 levels (up to 88 U ml-1). The CA 19-9 test can be useful as an additional diagnostic tool for the detection of pancreatic cancer. Preliminary results suggest that the CA 19-9 assay can be used in the monitoring of surgically treated patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>3456787</pmid><doi>10.1038/bjc.1986.35</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1986-02, Vol.53 (2), p.197-202 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2001324 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Alkaline Phosphatase - blood Antigens, Neoplasm - analysis Antigens, Tumor-Associated, Carbohydrate Biliary Tract Diseases - immunology Bilirubin - blood Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoembryonic Antigen - analysis Drug Resistance Epidemiology Gastroenterology. Liver. Pancreas. Abdomen Humans Jaundice - immunology Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Molecular Medicine Oncology original-article Pancreatic Neoplasms - immunology Pancreatitis - immunology Time Factors Tumors |
| title | Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A54%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20CA%2019-9%20as%20a%20serum%20tumour%20marker%20in%20pancreatic%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Haglund,%20C&rft.date=1986-02-01&rft.volume=53&rft.issue=2&rft.spage=197&rft.epage=202&rft.pages=197-202&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1986.35&rft_dat=%3Cproquest_pubme%3E76748481%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14347284&rft_id=info:pmid/3456787&rfr_iscdi=true |